|
Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
4/2022
vol. 124 abstract:
Original article
Episcleral brachytherapy for intraocular retinoblastoma with 106Ruthenium plaque: analysis of 13 procedures
Krzysztof Cieślik
1
,
Anna Rogowska
1
,
Małgorzata Danowska
1
,
Karolina Trocka
1
,
Olga Rutynowska
2
,
Bożenna Dembowska-Bagińska
2
,
Agnieszka Kołodziejczyk-Gietka
2
,
Ingeborga Charzyńska
3
,
Wojciech Hautz
1
1.
Department of Ophthalmology, Children’s Memorial Health Institute in Warsaw, Poland
2.
Department of Oncology, Children’s Memorial Health Institute in Warsaw, Poland
3.
Department of Nuclear Medicine, Children’s Memorial Health Institute in Warsaw, Poland
KLINIKA OCZNA 2022, 124, 4: 211-215
Online publish date: 2022/01/05
View full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Aim of the study
To evaluate the efficacy of 106Ru episcleral brachytherapy for the treatment of retinoblastoma. Material and methods Retrospective series of all 13 children with retinoblastoma treated with 106Ru plaques at the Department of Ophthalmology of the Children’s Memorial Health Institute in Warsaw between 01.01.2015 and 31.12.2020. Results A total of 13 tumors were treated with 106Ru brachytherapy. In all cases it was a salvage treatment for tumors resistant to other treatment modalities, after a mean of 3.15 relapses. Overall tumor control was achieved in 12 cases (92.3%). Tumor recurrence was observed in 1 case (7.7%) which led to enucleation. Radiation complications included persistent hemorrhages from neovascularization in 4 cases (30.8%). Conclusions 106Ru brachytherapy can be an effective salvage treatment for retinoblastoma. keywords:
episcleral brachytherapy, plaque radiotherapy, retinoblastoma, ruthenium |
|
POLSKI
